Xencor IncNASDAQ:XNCR
- LAST PRICE23.2000
- TODAY'S CHANGE (%)-0.2900 (-1.2346%)
- Bid / Lots23.2000/ 1
- Ask / Lots23.2300/ 3
- Open / Previous Close23.5000 / 23.4900
- Day Range
- 52 Week Range
- Volume94,682
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XNCR |
|---|---|---|
| 09:32 ET | 4873 | 23.3 |
| 09:34 ET | 1318 | 23.39 |
| 09:36 ET | 100 | 23.48 |
| 09:39 ET | 900 | 23.29 |
| 09:41 ET | 1573 | 23.3 |
| 09:43 ET | 100 | 23.305 |
| 09:45 ET | 300 | 23.395 |
| 09:48 ET | 1206 | 23.345 |
| 09:54 ET | 900 | 23.38 |
| 09:57 ET | 127 | 23.36 |
| 09:59 ET | 900 | 23.37 |
| 10:01 ET | 336 | 23.39 |
| 10:03 ET | 1850 | 23.32 |
| 10:06 ET | 200 | 23.315 |
| 10:10 ET | 695 | 23.3 |
| 10:12 ET | 100 | 23.27 |
| 10:14 ET | 200 | 23.26 |
| 10:15 ET | 100 | 23.22 |
| 10:17 ET | 100 | 23.22 |
| 10:19 ET | 934 | 23.25 |
| 10:21 ET | 300 | 23.3 |
| 10:24 ET | 200 | 23.33 |
| 10:26 ET | 200 | 23.33 |
| 10:28 ET | 600 | 23.315 |
| 10:30 ET | 100 | 23.31 |
| 10:33 ET | 900 | 23.36 |
| 10:35 ET | 238 | 23.39 |
| 10:37 ET | 1495 | 23.55 |
| 10:39 ET | 100 | 23.53 |
| 10:42 ET | 100 | 23.53 |
| 10:44 ET | 1100 | 23.45 |
| 10:46 ET | 825 | 23.42 |
| 10:48 ET | 600 | 23.45 |
| 10:50 ET | 200 | 23.39 |
| 10:53 ET | 996 | 23.35 |
| 10:55 ET | 300 | 23.37 |
| 10:57 ET | 100 | 23.35 |
| 11:00 ET | 454 | 23.45 |
| 11:02 ET | 1300 | 23.52 |
| 11:04 ET | 1100 | 23.37 |
| 11:08 ET | 200 | 23.45 |
| 11:09 ET | 700 | 23.47 |
| 11:13 ET | 3501 | 23.315 |
| 11:15 ET | 300 | 23.31 |
| 11:18 ET | 800 | 23.31 |
| 11:20 ET | 904 | 23.32 |
| 11:24 ET | 576 | 23.36 |
| 11:26 ET | 600 | 23.36 |
| 11:27 ET | 500 | 23.36 |
| 11:29 ET | 1100 | 23.34 |
| 11:33 ET | 200 | 23.28 |
| 11:36 ET | 1227 | 23.28 |
| 11:40 ET | 1200 | 23.31 |
| 11:44 ET | 100 | 23.33 |
| 11:49 ET | 500 | 23.29 |
| 11:51 ET | 1103 | 23.37 |
| 11:54 ET | 600 | 23.34 |
| 11:56 ET | 663 | 23.39 |
| 12:00 ET | 900 | 23.31 |
| 12:02 ET | 100 | 23.34 |
| 12:03 ET | 400 | 23.275 |
| 12:05 ET | 306 | 23.29 |
| 12:12 ET | 499 | 23.29 |
| 12:14 ET | 300 | 23.25 |
| 12:16 ET | 100 | 23.23 |
| 12:18 ET | 427 | 23.205 |
| 12:20 ET | 909 | 23.23 |
| 12:21 ET | 600 | 23.24 |
| 12:23 ET | 500 | 23.26 |
| 12:25 ET | 1300 | 23.16 |
| 12:32 ET | 100 | 23.15 |
| 12:34 ET | 300 | 23.16 |
| 12:38 ET | 1145 | 23.18 |
| 12:39 ET | 200 | 23.17 |
| 12:43 ET | 100 | 23.18 |
| 12:45 ET | 1100 | 23.23 |
| 12:48 ET | 1000 | 23.1801 |
| 12:50 ET | 100 | 23.18 |
| 12:52 ET | 100 | 23.23 |
| 12:54 ET | 200 | 23.2 |
| 12:56 ET | 400 | 23.2 |
May 10, 2024
DJ Xencor Is Maintained at Outperform by Wedbush, from 9:49AM ET on Friday May 10, 2024 by Dow Jones
9:49AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xencor Reports First Quarter 2024 Financial Results, from 4:09PM ET on Thursday May 09, 2024 by Dow Jones
4:09PM ET on Thursday May 09, 2024 by Dow Jones*DJ Xencor 1Q Loss/Shr $1.11 >XNCR, from 4:09PM ET on Thursday May 09, 2024 by Dow Jones
4:09PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xencor Inc | 1.5B | -10.6x | --- |
MannKind Corp | 1.3B | 199.3x | --- |
Ardelyx Inc | 1.6B | -24.7x | --- |
Arcus Biosciences Inc | 1.4B | -5.2x | --- |
Arcturus Therapeutics Holdings Inc | 1.0B | -11.0x | --- |
Mirum Pharmaceuticals Inc | 1.1B | -6.7x | --- |
Company Information
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Contact Information
- Headquarters
- 465 N. HALSTEAD ST., SUITE 200PASADENA, CA, United States 91107
- Phone
- 626-305-5900
- Fax
- 626-305-0350
Executives
- President, Chief Executive Officer, Founder and Director
- Bassil Dahiyat
- Senior Vice President, Chief Financial Officer
- Bart Cornelissen
- Executive Vice President - Research, Chief Scientific Officer
- John Desjarlais
- Executive Vice President, Chief Development Officer
- Nancy Valente
- Senior Vice President, General Counsel, Corporate Secretary
- Celia Eckert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $162.2M |
Shares Outstanding | 61.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-2.19 |
Book Value | $10.96 |
P/E Ratio | -10.6x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -97.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
